Claims
- 1. A hybrid protein derived from portions of the P. falciparum SERP and HRP-II antigen sequences consisting of the amino acid residues from about 630 to about 892 of the SERP antigen and the amino acid residues from about 364 to 552 of the HRP-II antigen.
- 2. A protein of claim 1 further comprising additional non-P. falciparum-derived amino acid sequences.
- 3. The MS2/SERP/HRPII fusion protein encoded by pEX SERP/HRPII as shown in FIG. 5.
- 4. A vaccine composition useful for reducing the severity of blood-stage malaria caused by P. falciparum comprising any one of the hybrid proteins of claims 1, 2, or 3, and a pharmaceutically acceptable excipient, carrier, or adjuvant.
- 5. A method of reducing the severity of blood-stage malaria caused by P. falciparum comprising administration of a vaccine composition of claim 4 to a subject.
- 6. A process of preparing a hybrid protein of any one of claims 1, 2, or 3 comprising (i) constructing a hybrid nucleic acid sequence which encodes a protein of any one of claims 1, 2 or 3, (ii) ligating said nucleic acid sequence into a suitable expression vector, (iii) transforming a suitable host cell with said expression vector under conditions suitable for expression of the hybrid nucleic acid sequence, and (iv) isolating a hybrid protein according to any one of claims 1, 2, or 3.
- 7. A hybrid protein derived from portions of the P. falciparum SERP, MSA I, and HRP-II antigen amino acid sequences consisting of the amino acid residues from about 630 to about 764 of the SERP antigen, the amino acid residues from about 140 to about 254 of the MSA I antigen, and the amino acid residues from about 364 to 552 of the HRP-II antigen.
- 8. A hybrid protein of claim 7 further comprising additional non-P. falciparum-derived amino acid sequences.
- 9. The SERP/MSA I/HRPII hybrid protein encoded by pTC2 HRPII as shown in FIG. 5.
- 10. A vaccine composition useful for reducing the severity of blood-stage malaria caused by P. falciparum comprising any one of the hybrid proteins of claims 7, 8 or 9, and a pharmaceutically acceptable excipient, carrier, or adjuvant.
- 11. A method of reducing the severity of blood-stage malaria caused by P. falciparum comprising administration of a vaccine composition of claim 10 to a subject.
- 12. A process of preparing a hybrid protein of any one of claims 7, 8 or 9 comprising (i) constructing a hybrid nucleic acid sequence which encodes a protein of any one of claims 7, 8 or 9, (ii) ligating said nucleic acid sequence into a suitable expression vector, (iii) transforming a suitable host cell with said expression vector under conditions suitable for expression of the hybrid nucleic acid sequence, and (iv) isolating a hybrid protein according to any one of claims 8, 9 or 10.
Priority Claims (1)
Number |
Date |
Country |
Kind |
40 41 836.7 |
Dec 1990 |
DEX |
|
Parent Case Info
This application is a continuation of application Ser. No. 08/017,446, filed Feb. 12, 1993, now abandoned, which is a continuation of application Ser. No. 07/806,471, filed Dec. 13, 1991, abandoned.
US Referenced Citations (3)
Foreign Referenced Citations (1)
Number |
Date |
Country |
0254862 |
Mar 1988 |
EPX |
Continuations (2)
|
Number |
Date |
Country |
Parent |
17446 |
Feb 1993 |
|
Parent |
806471 |
Dec 1991 |
|